TBPH Theravance Biopharma, Inc.

+0.46  (1%)
Previous Close 36.89
Open 37.00
Price To book 6.69
Market Cap 1.99B
Shares 53,361,000
Volume 195,176
Short Ratio 23.77
Av. Daily Volume 233,810

SEC filingsSee all SEC filings

  1. 8-K - Current report 17854980
  2. 8-K - Current report 17828328
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17828314
  4. 8-K - Current report 17826799
  5. DEF 14A - Other definitive proxy statements 17756079

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved June 21, 2013.
VIBATIV (telavancin hydrochloride) for injection
Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)
Approved April 30, 2015.
Phase 2a data due 2017.
Phase 3 study completion due 2018.
Closed Triple - CAPTAIN
NDA filing submission announced November 21, 2016.
Closed Triple
Phase 3 trials met primary endpoint. 12 month safety trial data (mid-2017) and NDA filing end of 2017.
Phase 2b initiated mid March 2015. Completion of study due mid-2017.
Velusetrag (TD-5108)
Phase 2 data released June 2016
Hepatitis C virus (HCV)
Phase 3 data due 2018.
Phase 3 first patient enrolled late February 2015. Data due 2017
Staphylococcus aureus bacteremia
Phase 3 data due in 2016
Chronic obstructive pulmonary disease (COPD

Latest News

  1. Novartis (NVS) Reports Positive Data on Ultibro Breezhaler
  2. Theravance/Mylan Presents Phase III Data on COPD Candidate
  3. Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS
  4. Theravance Biopharma, Inc. – Value Analysis (NASDAQ:TBPH) : May 19, 2017
  5. Theravance Biopharma, Inc. breached its 50 day moving average in a Bearish Manner : TBPH-US : May 18, 2017
  6. Theravance Biopharma and Mylan to Present Additional Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS
  7. Edited Transcript of TBPH earnings conference call or presentation 9-May-17 9:00pm GMT
  8. Theravance Bio reports 1Q loss
  9. Theravance Biopharma, Inc. Reports First Quarter 2017 Financial Results and Provides Business Update
  10. Investor Network: Theravance Biopharma Inc to Host Earnings Call
  11. Theravance Biopharma to Report First Quarter 2017 Financial Results on May 9, 2017
  12. Theravance Biopharma to Present at the Deutsche Bank 42nd Annual Health Care Conference
  13. New Data for VIBATIV® (telavancin) Reported in Several Presentations at ECCMID 2017
  14. Theravance Biopharma Reports Positive Clinical Response Rates for Patients in TOUR™ Observational Patient Registry in Several Presentations at ECCMID 2017
  15. Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin), Including Preliminary Results from TOUR™ Observational Patient Registry, at 2017 ECCMID Conference
  16. Theravance (TBPH) Up 17.5% Since Earnings Report: Can It Continue?
  17. Theravance Biopharma to Present at the 16th Annual Needham Healthcare Conference